Genmab presents full data set for cancer drug
In April, the biotech firm released topline results from a phase II study of its treatment for large B-cell lymphoma, epcoritamab, and Genmab has now revealed the full picture.
by marketwire, translated by daniel pedersen
On Saturday, Genmab reported all data from a successful phase II study of drug candidate epcoritamab as a treatment for large B-cell lymphoma (LBCL).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Cancer drug hope raises Genmab's spirits after legal defeat
For subscribers
Genmab receives orphan drug designation from FDA
For subscribers
.jpg)
.jpg&w=384&q=75)
